Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after 1,4-butanediol administration to healthy volunteers

被引:45
作者
Thai, D.
Dyer, J. E.
Jacob, P.
Haller, C. A. [1 ]
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Div Clin Pharmacol, Dept Med, San Francisco, CA 94143 USA
[2] Amgen Corp, Thousand Oaks, CA USA
[3] Univ Calif San Francisco, California Poison Control Syst, Dept Clin Pharm, San Francisco, CA 94143 USA
关键词
D O I
10.1038/sj.clpt.6100037
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1,4-Butanediol (BD) is converted to gamma-hydroxybutyrate (GHB) after ingestion, and is associated with cases of dependence, coma, and death. The pharmacology of BD after oral ingestion has not been described in humans. Eight healthy volunteers (five men) were administered 25 mg/kg BD in a single oral dose after an overnight fast in a double-blinded, placebo-controlled, crossover study. Vital signs were monitored, and serial blood samples collected over 24 h for gas chromatography-mass spectrometry analysis of BD and GHB levels. Subjective mood and symptoms responses were assessed by visual analog scale. All subjects completed the study without significant adverse effects. BD was quickly absorbed and cleared, with time-to maximal plasma concentration of 24 +/- 12 min, and elimination half-life (T-1/2) of 39.3 +/- 11 min. BD was extensively converted to GHB, with a mean maximum GHB concentration of 45.6 +/- 19.7 mg/l reached 39.4 +/- 11.2 min after BD ingestion. GHB T-1/2 averaged 32.3 +/- 6.6 min. Some subjects exhibited slow oral clearance of BD, which tended to correlate with a variant haplotype of the alcohol dehydrogenase gene ADH-IB G143A. Mean CL/F was 151.5 +/- 176.5 ml/min kg for four subjects with variant haplotype versus 598.8 +/- 446.6 ml/min kg for four wild-type subjects (P = 0.061). Subjects reported feeling less awake and alert, less able to concentrate, and more lightheaded in the first 90 min after BD ingestion. Pulse oximetry readings were lower 45 min after BD dosing with a mean oxygen saturation of 98.5% with 1313 versus 99.6% with placebo (P = 0.031). Transient increases in mean systolic and diastolic blood pressure were observed, but other vital signs remained unchanged. BD was extensively converted to GHB after oral administration, but significant inter-individual variability in the rate of metabolism, possibly related to variants in ADH-IB, was observed. At the modest dose studied, significant clinical effects were not seen.
引用
收藏
页码:178 / 184
页数:7
相关论文
共 47 条
  • [1] Trends in γ-hydroxybutyrate (GHB) and related drug intoxication:: 1999 to 2003
    Anderson, IB
    Kim, SY
    Dyer, JE
    Burkhardt, CB
    Iknoian, JC
    Walsh, MJ
    Blanc, PD
    [J]. ANNALS OF EMERGENCY MEDICINE, 2006, 47 (02) : 177 - 183
  • [2] Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) and its metabolic precursor, gamma-butyrolactone (GBL) in rats
    Baker, LE
    Van Tilburg, TJ
    Brandt, AE
    Poling, A
    [J]. PSYCHOPHARMACOLOGY, 2005, 181 (03) : 458 - 466
  • [3] 1,4-BUTANEDIOL - SUBSTRATE FOR RAT-LIVER AND HORSE LIVER ALCOHOL DEHYDROGENASES
    BESSMAN, SP
    MCCABE, RB
    [J]. BIOCHEMICAL PHARMACOLOGY, 1972, 21 (08) : 1135 - +
  • [4] The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients
    Borgen, LA
    Okerholm, RA
    Lai, A
    Scharf, MB
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (03) : 253 - 257
  • [5] The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects
    Borgen, LA
    Okerholm, R
    Morrison, D
    Lai, A
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (01) : 59 - 65
  • [6] Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects
    Brenneisen, R
    ElSohly, MA
    Murphy, TP
    Passarelli, J
    Russmann, S
    Salamone, SJ
    Watson, DE
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2004, 28 (08) : 625 - 630
  • [7] Fatalities associated with the use of γ-hydroxybutyrate and its analogues in Australasia
    Caldicott, DGE
    Chow, FY
    Burns, BJ
    Felgate, PD
    Byard, RW
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2004, 181 (06) : 310 - +
  • [8] Resuscitative treatments on 1,4-butanediol mortality in mice
    Carai, MAM
    Colombo, G
    Quang, LS
    Maher, TJ
    Gessa, GL
    [J]. ANNALS OF EMERGENCY MEDICINE, 2006, 47 (02) : 184 - 189
  • [9] Withdrawal syndrome from γ-hydroxybutyric acid (GHB) and 1,4-butanediol (1,4-BD) in Sardinian alcohol-preferring rats
    Carai, MAM
    Quang, LS
    Atzeri, S
    Lobina, C
    Maccioni, P
    Orrù, A
    Gessa, GL
    Maher, TJ
    Colombo, G
    [J]. BRAIN RESEARCH PROTOCOLS, 2005, 15 (02): : 75 - 78
  • [10] Central effects of 1,4-butanediol are mediated by GABAB receptors via its conversion into γ-hydroxybutyric acid
    Carai, MAM
    Colombo, G
    Reali, R
    Serra, S
    Mocci, I
    Castelli, MP
    Cignarella, G
    Gessa, GL
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 441 (03) : 157 - 163